

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4531297

| | |
|---|--|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | ASSIGNMENT |
| CONVEYING PARTY DATA | |
| Name | Execution Date |
| SOPHARMIA, INC. | 06/22/2015 |
| RECEIVING PARTY DATA | |
| Name: | GLADIUS PHARMACEUTICALS CORPORATION |
| Street Address: | 3575 AVENUE DU PARC, LOCAL 4310 |
| City: | MONTREAL, QUEBEC |
| State/Country: | CANADA |
| Postal Code: | H2X3P9 |
| PROPERTY NUMBERS Total: 1 | |
| Property Type | Number |
| Application Number: | 15656845 |
| CORRESPONDENCE DATA | |
| Fax Number: | (720)931-3001 |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | |
| Phone: | 7209313000 |
| Email: | cnelson@lathropgage.com, boulderip@lathropgage.com |
| Correspondent Name: | LATHROP GAGE LLP |
| Address Line 1: | 4845 PEARL EAST CIRCLE, SUITE 201 |
| Address Line 4: | BOULDER, COLORADO 80301 |
| ATTORNEY DOCKET NUMBER: | 593085: 169-08C US |
| NAME OF SUBMITTER: | SALLY A. SULLIVAN |
| SIGNATURE: | /sallyasullivan/ |
| DATE SIGNED: | 08/01/2017 |
| Total Attachments: 4 | |
| source=169-08C_US_assgn_sopharmia-gladius#page1.tif | |
| source=169-08C_US_assgn_sopharmia-gladius#page2.tif | |
| source=169-08C_US_assgn_sopharmia-gladius#page3.tif | |
| source=169-08C_US_assgn_sopharmia-gladius#page4.tif | |


WORLDWIDE ASSIGNMENT

We, **Sopharmia, Inc.**, whose full post office address is 4221 Mitchell Ave Saint Joseph, MO 64507 US, in consideration of the sum of Ten Dollars (\$10.00), the receipt and sufficiency of which are hereby acknowledged, do hereby sell and assign to **Gladius Pharmaceuticals Corporation** (hereinafter referred to as "said Assignee"), its successors and assigns, whose full post office address is ~~1000 de la Gauchetière Street West, Suite 2100, Montréal, Québec H3B-4W5~~, *3575 Avenue du Parc, local 4310 Montréal Québec H2X 3P9 Canada*, all our right, title and interest in the United States of America and worldwide, as fully described and claimed in and to our patents and patent applications listed in **Schedule A** to this assignment, for such inventions, including any and all priority rights derived therefrom, and the right, where such right can be legally exercised, in its own name to apply for and obtain Letters Patents, Inventor's Certificates, Utility Models and Design Patents, in the United States and all foreign countries, and the entire interest in any Letters Patent, Inventor's Certificate, Utility Model or Design Patent which may be granted on any such applications, including any and all divisionals and continuations of said application, in the United States of America, and countries foreign to the United States of America, including any reissues and extensions thereof.


And for the above-named consideration, we hereby agree that we will, without additional compensation but without cost to us, promptly communicate to said assignee its successors and assigns, any facts known to us respecting said invention whenever requested, and testify in any legal proceedings, sign all lawful papers, execute all divisional, continuation and reissue applications for Letters Patent, Inventor's Certificates, Utility Models and Designs and assignments thereof, make all rightful oaths and generally do everything possible to aid our said

assignee, its successors and assigns, as and when requested by them, in obtaining and enforcing proper patent, utility model and design protection for said invention or inventions and improvements, in the United States of America and in all other countries.

SIGNED at Montreal, this 22 day of June, 2015.



Signature of Witness



Name: Michael Aitken
Title: chairman

SCHEDULE A

PATENTS

| L & G Reference | Application No. | Patent No. | Country | Status | Subject Matter Summary |
|---|-------------------------------------|--|---------|------------------------|---|
| Broad Spectrum Beta-Lactamase Inhibitors | | | | | |
| US provisional A | 60/997,898 Filed: 10/09/2007 | | US | Converted/ Inactive | |
| US provisional B | 60/997,941 Filed: 10/09/2007 | | US | Converted/ Inactive | |
| 536214 169-08 US | 12/248,760 Filed: 10/09/2008 | 8,883,772 Issued: 11/11/ 2014 | US | Granted | Issued claims: Compounds Cephem Cores having antibiotic and beta-lactamase activity; Method of treatment of bacterial infections, Methods of inhibiting the growth of a bacterium; Methods for inhibiting a beta-lactamase. |
| 554996 169-08A US | 14/491,806 Filed: 09/ 19/2014 | | US | Pending | Compounds other than Cephem Cores having antibiotic and beta-lactamase activity; Methods of inhibiting the growth of a bacterium; Methods for inhibiting a beta-lactamase. |
| 536215 169-08 WO | US08/79410 Filed: 10/09/2008 | | PCT | Converted/ Inactive | Compounds with Cephem and other Cores having antibiotic and beta-lactamase activity; Methods of inhibiting the growth of a bacterium; Methods for inhibiting a beta-lactamase. |
| 536211 169-08 CA | 2,702,257 Filed: 10/09/2008 | | CA | Pending | (currently same as WO) |
| 536212 169-08 EP | 08837969.8 Filed: 10/09/2008 | | EP | Pending | Pending claims similar to US granted claims |

| L & G Reference | Application No. | Patent No. | Country | Status | Subject Matter Summary |
|--------------------------------|---|--------------------------------|---------|--|---|
| 536213 169-08 JP | 2010-529054 Filed: 10/09/2008 | 5733856 Issued 4/24/2015 | JP | Granted | Compounds Cephem Cores having antibiotic and beta-lactamase activity; Method of treatment of bacterial infections, Methods of inhibiting the growth of a bacterium; Methods for inhibiting a beta-lactamase. |
| 568863 169-08 JP1 | 2015-081763 Filed: April 13, 2015 | | JP | Pending | Compounds other than Cephem Cores having antibiotic and beta-lactamase activity; Method of treatment of bacterial infections, Methods of inhibiting the growth of a bacterium; Methods for inhibiting a beta-lactamase. |
| 3-Styryl-Cephalosporins | | | | | |
| 554741 17-14P US | 61/778,378 Filed 03/12/2013 | | US | Converted/ Inactive | 3-Styryl-Cephalosporins; Methods of treatment of bacterial infections; Methods of inhibiting the growth of a bacterium |
| 554740 17-14 WO | US14/24503 Filed: 03/12/2014 | | WO | Pending; Positive IPRP/National Stage Filing Deadline (30- month) Sept, 2015 | 3-Styryl-Cephalosporins; Methods of treatment of bacterial infections; Methods of inhibiting the growth of a bacterium |